Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

Glutamatergic Modulation to Facilitate Naltrexone Initiation: A Randomized, Controlled Trial

To see complete record on, please visit this link

Id: NCT03345173

Organisation Name: New York State Psychiatric Institute

Overal Status: Recruiting

Start Date: November 25, 2017

Last Update: December 1, 2022

Lead Sponsor: New York State Psychiatric Institute

Brief Summary: The incidence of opioid use disorders (OUDs) has increased to near-epidemic proportions. While maintenance with long-acting opioids such as methadone or buprenorphine represents an effective treatment strategy, it may be unacceptable to many individuals. As a result, long-acting injectable naltrexone (XR-NTX), an antagonist medication that blocks the effects of opioids for at least 4 weeks, is now indicated for relapse prevention following detoxification. This randomized, controlled trial aims to test the efficacy of a glutamate modulator at facilitating a rapid non-opioid based naltrexone induction.

  • Opioid Dependence

Total execution time in seconds: 0.28881812095642